Postoperative surgical site infections (SSIs) in neurosurgical patients carry a significant risk of increased morbidity and mortality. With SSIs accounting for approximately 20% of nosocomial infections and costing approximately $1.6 billion USD annually, there is a need for additional prophylaxis to improve current standards of care. Topical vancomycin is increasingly utilized in instrumented spinal and cardiothoracic procedures, where it has been shown to reduce the risk of SSIs. A randomized controlled trial assessing its efficacy in the general neurosurgical population is currently underway. Here, the authors report their initial impressions of topical vancomycin safety among patients enrolled during the 1st year of the trial.
This prospective, multicenter, patient-blinded, randomized controlled trial will enroll 2632 patients over 5 years. Here, the authors report the incidence of adverse events, the degree of systemic vancomycin absorption in treated patients, and pattern changes of antibiotic-resistant profiles of Staphylococcus aureus flora among patients enrolled during the 1st year.
The topical vancomycin treatment group comprised 257 patients (514 total enrolled patients), of whom 2 exhibited weakly positive serum levels of vancomycin (> 3.0 mg/dl). S. aureus was detected preoperatively in the anterior nares of 35 (18.1%) patients and the skin near the surgical site of 9 (4.7%). Colonization in the nares remained for many patients (71.4%) through postoperative day 30. The authors found a significant association between preoperative S. aureus colonization and postoperative colonization. Seven methicillin-resistant isolates were detected among 6 different patients. Two isolates were detected preoperatively, and 5 were de novo postoperative colonization. No adverse responses to treatment have been reported to date.
The authors’ data indicate that the use of topical vancomycin is safe with no significant adverse effects and minimal systemic absorption, and no development of vancomycin-resistant microorganisms.
Alcalá-CerraGPaternina-CaicedoAJMoscote-SalazarLRGutiérrez-PaterninaJJNiño-HernándezLM: [Application of vancomycin powder into the wound during spine surgery: systematic review and meta-analysis.]Rev Esp Cir Ortop Traumatol58:182–1912014(Span)
ChaichanaKLBydonMSantiago-DieppaDRHwangLMcLoughlinGSciubbaDM: Risk of infection following posterior instrumented lumbar fusion for degenerative spine disease in 817 consecutive cases. J Neurosurg Spine20:45–522014
ChauvSFontaineGVHoangQPMcKinneyCBBaldwinMBuckelWR: Risk of resistant organisms and Clostridium difficile with prolonged systemic antibiotic prophylaxis for central nervous system devices. Neurocrit Care25:128–1322016
DavisKAStewartJJCrouchHKFlorezCEHospenthalDR: Methicillin-resistant Staphylococcus aureus (MRSA) nares colonization at hospital admission and its effect on subsequent MRSA infection. Clin Infect Dis39:776–7822004
EngemannJJCarmeliYCosgroveSEFowlerVGBronsteinMZTrivetteSL: Adverse clinical and economic outcomes attributable to methicillin resistance among patients with Staphylococcus aureus surgical site infection. Clin Infect Dis36:592–5982003
FinkelsteinRRabinoGMashiahTBar-ElYAdlerZKertzmanV: Vancomycin versus cefazolin prophylaxis for cardiac surgery in the setting of a high prevalence of methicillin-resistant staphylococcal infections. J Thorac Cardiovasc Surg123:326–3322002
HanZLautenbachEFishmanNNachamkinI: Evaluation of mannitol salt agar, CHROMagar Staph aureus and CHROMagar MRSA for detection of meticillin-resistant Staphylococcus aureus from nasal swab specimens. J Med Microbiol56:43–462007
HarbarthSFankhauserCSchrenzelJChristensonJGervazPBandiera-ClercC: Universal screening for methicillin-resistant Staphylococcus aureus at hospital admission and nosocomial infection in surgical patients. JAMA299:1149–11572008
HarrisPATaylorRThielkeRPayneJGonzalezNCondeJG: Research electronic data capture (REDCap)—a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform42:377–3812009
JonokuchiAJKnopmanJRadwanskiREMartinezMATaylorBESRothbaumM: Topical vancomycin to reduce surgical-site infections in neurosurgery: Study protocol for a multi-center, randomized controlled trial. Contemp Clin Trials64:195–2002018
LassenBHelsethERønningPScheieDJohannesenTBMæhlenJ: Surgical mortality at 30 days and complications leading to recraniotomy in 2630 consecutive craniotomies for intracranial tumors. Neurosurgery68:1259–12692011
Lexicomp: Vancomycin: drug information. UpToDate. (https://www.uptodate.com/contents/vancomycin-drug-information?search=Vancomycin:%20Drug%20Information&source=search_result&selectedTitle=1∼148&usage_type=default&display_rank=1) [Accessed August 23 2018]
O’NeillKRSmithJGAbtahiAMArcherKRSpenglerDMMcGirtMJ: Reduced surgical site infections in patients undergoing posterior spinal stabilization of traumatic injuries using vancomycin powder. Spine J11:641–6462011
Pardos de la GandaraMRaygoza GarayJAMwangiMTobinJNTsangAKhalidaC: Molecular types of methicillin-resistant Staphylococcus aureus and Methicillin-sensitive S. aureus strains causing skin and soft tissue infections and nasal colonization, identified in community health centers in New York City. J Clin Microbiol53:2648–26582015
SharpSESearcyC: Comparison of mannitol salt agar and blood agar plates for identification and susceptibility testing of Staphylococcus aureus in specimens from cystic fibrosis patients. J Clin Microbiol44:4545–45462006
XiongLPanQJinGXuYHircheC: Topical intrawound application of vancomycin powder in addition to intravenous administration of antibiotics: a meta-analysis on the deep infection after spinal surgeries. Orthop Traumatol Surg Res100:785–7892014